Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the European Institute of Oncology Group

Seminars in Nuclear Medicine

Volumn 32, Issue 2, 2002, Pages 141-147

  Chinol, Marco ^a   Bodei, Lisa ^a   Cremonesi, Marta ^a   Paganelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE[1 DEXTRO PHENYLALANINE 3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; PENTETREOTIDE; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN CANCER; CANCER SURVIVAL; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PANCREAS CANCER; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; THYROID CANCER; TISSUE DISTRIBUTION;

EID: 0036229521     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.31563     Document Type: Article

References (29)

1. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro
2. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
3. 3]-octreotide: The Rotterdam experience with more than 1000 patients
4. Somatostatin-receptor imaging in the localization of endocrine tumors
5. High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interactions?
6. Somatostatin receptors and theirs subtypes in human tumors and in peritumoral vessels
7. 111In-pentetreotide
8. Receptor targeting for tumor localisation and therapy with radiopeptides
9. 90Y from cyclic and acyclic ligand-antibody conjugates
10. The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitroben-zyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetra-acetic acid and study of its Yttrium(III) complex
11. Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent
12. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
13. DOTATOC-a new powerful tool for receptor- mediated radionuclide therapy
14. 3-octreotide: Preliminary report in cancer patients
15. Affinity profiles for human somatostatin receptor subtypes SST1-SST 5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
16. 3]octreotide, a promising somatostatin analogue for radionuclide therapy
17. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
18. 90Y-DOTATOC
19. 1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: Synthesis, radiolabelling and in vitro validation
20. Reporting results of cancer treatment
21. 1]-octreotide. A case history
22. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy
23. 3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
24. Yttrium-90-labelled somatostatin-analogue for cancer treatment
25. Yttrium-90 DOTATOC: First clinical results
26. TM): A phase I study
27. 86y] SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
28. 90Y-DOTATOC: Dosimetric evaluations
29. 0]octreotide in patients